BiVictriX Therapeutics' Chief Executive Officer and Founder Tiffany Thorn joins Proactive London's Katie Pilbeam to discuss their intention to list on AIM, 'signifying a new chapter in our company’s long term development'.
The listing is being done to accelerate the firm's growth as well as accelerate their highly selective cancer therapeutics, based on their proprietary Bi-Cygni® platform.
Tiffany explains their method, by targeting a combination of antigens expressed primarily on cancer cells, their unique approach enables clinicians to treat patients with higher precision and potentially higher doses of medication. And without causing harmful side-effects to the patient.